Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium.
We have previously reported expression of vascular endothelial growth factor (VEGF)-A and -C in glomerular podocytes and actions of VEGF-A on glomerular endothelial cells (GEnC) that express VEGF receptor-2 (VEGFR-2). Here we define VEGFR-3 expression in GEnC and investigate the effects of the ligand VEGF-C. Renal cortex and cultured GEnC were examined by microscopy, and both cell and glomerular lysates were assessed by Western blotting. VEGF-C effects on trans-endothelial electrical resistance and albumin flux across GEnC monolayers were measured. The effects of VEGF-C156S, a VEGFR-3-specific agonist, and VEGF-A were also studied. VEGF-C effects on intracellular calcium ([Ca2+]i) were measured using a fluorescence technique, receptor phosphorylation was examined by immunoprecipitation assays, and phosphorylation of myosin light chain-2 and VE-cadherin was assessed by blotting with phospho-specific antibodies. GEnC expressed VEGFR-3 in tissue sections and culture, and VEGF-C increased trans-endothelial electrical resistance in a dose-dependent manner with a maximal effect at 120 minutes of 6.8 Omega whereas VEGF-C156S had no effect. VEGF-C reduced labeled albumin flux by 32.8%. VEGF-C and VEGF-A increased [Ca2+]i by 15% and 39%, respectively. VEGF-C phosphorylated VEGFR-2 but not VEGFR-3, myosin light chain-2, or VE-cadherin. VEGF-C increased GEnC monolayer integrity and increased [Ca2+]i, which may be related to VEGF-C-S particular receptor binding and phosphorylation induction characteristics. These observations suggest that podocytes direct GEnC behavior through both VEGF-C and VEGF-A.
Foster
Rebecca R
RR
Academic Renal Unit, Southmead Hospital, Bristol, UK.
Slater
Sadie C
SC
Seckley
Jaqualine
J
Kerjaschki
Dontscho
D
Bates
David O
DO
Mathieson
Peter W
PW
Satchell
Simon C
SC
D015703:Antigens, CD / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D020013:Calcium Signaling / Q000187:drug effects; D024722:Cardiac Myosins / Q000378:metabolism; D002460:Cell Line; D017097:Electric Impedance; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D016650:Fluorescein-5-isothiocyanate / Q000378:metabolism; D006801:Humans; D042541:Intracellular Space / Q000187:drug effects / Q000378:metabolism*; D007678:Kidney Glomerulus / Q000166:cytology* / Q000502:physiology* / Q000648:ultrastructure; D050505:Mutant Proteins / Q000494:pharmacology; D018994:Myosin Light Chains / Q000378:metabolism; D019899:Paracrine Communication / Q000187:drug effects*; D010539:Permeability / Q000187:drug effects; D010766:Phosphorylation / Q000187:drug effects; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology; D042582:Vascular Endothelial Growth Factor C / Q000494:pharmacology*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000378:metabolism / Q000648:ultrastructure; D000099152:Cadherin 5
D015703:Antigens, CD; D015820:Cadherins; D002118:Calcium; D024722:Cardiac Myosins; D016650:Fluorescein-5-isothiocyanate; D050505:Mutant Proteins; D018994:Myosin Light Chains; D042461:Vascular Endothelial Growth Factor A; D042582:Vascular Endothelial Growth Factor C; D040301:Vascular Endothelial Growth Factor Receptor-2; D040321:Vascular Endothelial Growth Factor Receptor-3; D000099152:Cadherin 5; C107184:myosin light chain 2
Blood. 2000 Jul 15;96(2):546-53
10887117
Am J Physiol Renal Physiol. 2004 Apr;286(4):F767-73
14644752
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2019-26
16794222
J Anat. 2002 Jun;200(6):581-97
12162726
Am J Physiol. 1995 Feb;268(2 Pt 2):F240-50
7864162
Am J Pathol. 2001 Aug;159(2):599-608
11485918
Nat Med. 2001 Feb;7(2):199-205
11175851
J Cell Sci. 1995 Jun;108 ( Pt 6):2369-79
7673356
Tohoku J Exp Med. 2001 Sep;195(1):43-54
11780723
J Biol Chem. 2003 Apr 11;278(15):12605-8
12538598
Oncogene. 1994 Dec;9(12):3545-55
7970715
EMBO J. 2001 Mar 15;20(6):1223-31
11250889
J Am Soc Nephrol. 2004 Mar;15(3):566-74
14978158
Blood. 2000 Dec 1;96(12):3793-800
11090062
Curr Top Microbiol Immunol. 1999;237:85-96
9893347
J Vasc Res. 2001 Mar-Apr;38(2):176-86
11316953
J Anat. 2002 Jun;200(6):549-60
12162723
EMBO J. 1997 Jul 1;16(13):3898-911
9233800
Nat Med. 1999 Dec;5(12):1359-64
10581076
Kidney Int. 2006 May;69(9):1633-40
16557232
Nat Med. 2003 Jul;9(7):936-43
12796773
J Clin Invest. 2003 Mar;111(5):707-16
12618525
Science. 1998 Oct 30;282(5390):946-9
9794766
J Histochem Cytochem. 2002 Jun;50(6):767-77
12019293
J Biol Chem. 2003 Oct 17;278(42):40973-9
12881528
J Biol Chem. 1998 Mar 20;273(12):6599-602
9506953
J Cell Sci. 1998 Jul;111 ( Pt 13):1853-65
9625748
J Am Soc Nephrol. 2002 Feb;13(2):544-550
11805186
Development. 1996 Dec;122(12):3829-37
9012504
Am J Physiol. 1990 May;258(5 Pt 2):H1366-74
2337172
Circ Res. 2005 Apr 29;96(8):856-63
15790951
Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1625-34
11009449
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70
7724599
Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76
16172168
Science. 1997 May 30;276(5317):1423-5
9162011
Am J Physiol Renal Physiol. 2006 Jul;291(1):F196-207
16525158
Circ Res. 2005 Jun 24;96(12):1282-90
15920022
Circ Res. 2003 May 30;92(10):1098-106
12714562
J Nephrol. 2003 Mar-Apr;16(2):168-78
12768063
J Biol Chem. 2004 Aug 20;279(34):36148-57
15215251
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14389-94
9826710
Eur J Biochem. 2001 Nov;268(21):5530-40
11683876
Exp Cell Res. 1999 Nov 25;253(1):117-30
10579917
EMBO J. 2001 Sep 3;20(17):4762-73
11532940
J Physiol. 2005 May 1;564(Pt 3):817-27
15718259
Blood. 2003 Feb 15;101(4):1367-74
12393458
Circ Res. 2004 Mar 19;94(5):664-70
14739162
Am J Pathol. 1989 Feb;134(2):481-9
2521774
FASEB J. 2000 Oct;14(13):2087-96
11023993